Filtered By:
Condition: Arthritis
Infectious Disease: Tuberculosis
Therapy: Statin Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Anti-inflammatory drug may help prevent heart attacks
Conclusion This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past. But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose. Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection. They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news